nodes	percent_of_prediction	percent_of_DWPC	metapath
Felbamate—CYP2E1—Mitoxantrone—lymphatic system cancer	0.152	0.305	CbGbCtD
Felbamate—CYP2C19—Teniposide—lymphatic system cancer	0.137	0.273	CbGbCtD
Felbamate—CYP3A4—Cytarabine—lymphatic system cancer	0.0671	0.134	CbGbCtD
Felbamate—CYP3A4—Teniposide—lymphatic system cancer	0.0661	0.132	CbGbCtD
Felbamate—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0462	0.0924	CbGbCtD
Felbamate—CYP3A4—Vincristine—lymphatic system cancer	0.0318	0.0636	CbGbCtD
Felbamate—Visual impairment—Carmustine—lymphatic system cancer	0.000715	0.00143	CcSEcCtD
Felbamate—Fatigue—Fludarabine—lymphatic system cancer	0.00071	0.00142	CcSEcCtD
Felbamate—Hallucination—Vincristine—lymphatic system cancer	0.000705	0.00141	CcSEcCtD
Felbamate—Pain—Fludarabine—lymphatic system cancer	0.000704	0.00141	CcSEcCtD
Felbamate—Constipation—Fludarabine—lymphatic system cancer	0.000704	0.00141	CcSEcCtD
Felbamate—Bradycardia—Mitoxantrone—lymphatic system cancer	0.000702	0.0014	CcSEcCtD
Felbamate—Vasculitis—Methotrexate—lymphatic system cancer	0.000701	0.0014	CcSEcCtD
Felbamate—Respiratory failure—Methotrexate—lymphatic system cancer	0.000697	0.00139	CcSEcCtD
Felbamate—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000693	0.00139	CcSEcCtD
Felbamate—Rhinitis—Mitoxantrone—lymphatic system cancer	0.000692	0.00138	CcSEcCtD
Felbamate—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00069	0.00138	CcSEcCtD
Felbamate—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00069	0.00138	CcSEcCtD
Felbamate—Flushing—Carmustine—lymphatic system cancer	0.000689	0.00138	CcSEcCtD
Felbamate—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000687	0.00137	CcSEcCtD
Felbamate—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.000685	0.00137	CcSEcCtD
Felbamate—Anaemia—Bleomycin—lymphatic system cancer	0.000684	0.00137	CcSEcCtD
Felbamate—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000679	0.00136	CcSEcCtD
Felbamate—Asthenia—Teniposide—lymphatic system cancer	0.000672	0.00135	CcSEcCtD
Felbamate—Malaise—Bleomycin—lymphatic system cancer	0.000667	0.00134	CcSEcCtD
Felbamate—Pruritus—Teniposide—lymphatic system cancer	0.000663	0.00133	CcSEcCtD
Felbamate—Leukopenia—Bleomycin—lymphatic system cancer	0.000662	0.00133	CcSEcCtD
Felbamate—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.000661	0.00132	CcSEcCtD
Felbamate—Alopecia—Carmustine—lymphatic system cancer	0.000656	0.00131	CcSEcCtD
Felbamate—Body temperature increased—Fludarabine—lymphatic system cancer	0.000651	0.0013	CcSEcCtD
Felbamate—Cough—Bleomycin—lymphatic system cancer	0.000646	0.00129	CcSEcCtD
Felbamate—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.000643	0.00129	CcSEcCtD
Felbamate—Diarrhoea—Teniposide—lymphatic system cancer	0.000641	0.00128	CcSEcCtD
Felbamate—Chest pain—Bleomycin—lymphatic system cancer	0.00063	0.00126	CcSEcCtD
Felbamate—Myalgia—Bleomycin—lymphatic system cancer	0.00063	0.00126	CcSEcCtD
Felbamate—Alopecia—Vincristine—lymphatic system cancer	0.000626	0.00125	CcSEcCtD
Felbamate—Coma—Methotrexate—lymphatic system cancer	0.000625	0.00125	CcSEcCtD
Felbamate—Discomfort—Bleomycin—lymphatic system cancer	0.000622	0.00125	CcSEcCtD
Felbamate—Chills—Mitoxantrone—lymphatic system cancer	0.000619	0.00124	CcSEcCtD
Felbamate—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000619	0.00124	CcSEcCtD
Felbamate—Neoplasm—Methotrexate—lymphatic system cancer	0.000619	0.00124	CcSEcCtD
Felbamate—Alopecia—Mitoxantrone—lymphatic system cancer	0.00061	0.00122	CcSEcCtD
Felbamate—Confusional state—Bleomycin—lymphatic system cancer	0.000609	0.00122	CcSEcCtD
Felbamate—Tremor—Carmustine—lymphatic system cancer	0.000605	0.00121	CcSEcCtD
Felbamate—Oedema—Bleomycin—lymphatic system cancer	0.000604	0.00121	CcSEcCtD
Felbamate—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000604	0.00121	CcSEcCtD
Felbamate—Infection—Bleomycin—lymphatic system cancer	0.0006	0.0012	CcSEcCtD
Felbamate—Anaemia—Carmustine—lymphatic system cancer	0.000597	0.00119	CcSEcCtD
Felbamate—Vomiting—Teniposide—lymphatic system cancer	0.000596	0.00119	CcSEcCtD
Felbamate—Sepsis—Methotrexate—lymphatic system cancer	0.000594	0.00119	CcSEcCtD
Felbamate—Agitation—Carmustine—lymphatic system cancer	0.000594	0.00119	CcSEcCtD
Felbamate—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000591	0.00118	CcSEcCtD
Felbamate—Asthenia—Fludarabine—lymphatic system cancer	0.000591	0.00118	CcSEcCtD
Felbamate—Rash—Teniposide—lymphatic system cancer	0.000591	0.00118	CcSEcCtD
Felbamate—Dermatitis—Teniposide—lymphatic system cancer	0.00059	0.00118	CcSEcCtD
Felbamate—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000588	0.00118	CcSEcCtD
Felbamate—Headache—Teniposide—lymphatic system cancer	0.000587	0.00117	CcSEcCtD
Felbamate—Pruritus—Fludarabine—lymphatic system cancer	0.000583	0.00117	CcSEcCtD
Felbamate—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000582	0.00116	CcSEcCtD
Felbamate—Leukopenia—Carmustine—lymphatic system cancer	0.000578	0.00116	CcSEcCtD
Felbamate—Anorexia—Bleomycin—lymphatic system cancer	0.000576	0.00115	CcSEcCtD
Felbamate—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000574	0.00115	CcSEcCtD
Felbamate—Anaemia—Vincristine—lymphatic system cancer	0.00057	0.00114	CcSEcCtD
Felbamate—Agitation—Vincristine—lymphatic system cancer	0.000567	0.00113	CcSEcCtD
Felbamate—Hypotension—Bleomycin—lymphatic system cancer	0.000564	0.00113	CcSEcCtD
Felbamate—Diarrhoea—Fludarabine—lymphatic system cancer	0.000564	0.00113	CcSEcCtD
Felbamate—Hypertension—Carmustine—lymphatic system cancer	0.000558	0.00112	CcSEcCtD
Felbamate—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000557	0.00111	CcSEcCtD
Felbamate—Nausea—Teniposide—lymphatic system cancer	0.000557	0.00111	CcSEcCtD
Felbamate—Anaemia—Mitoxantrone—lymphatic system cancer	0.000555	0.00111	CcSEcCtD
Felbamate—Hepatic failure—Methotrexate—lymphatic system cancer	0.000553	0.00111	CcSEcCtD
Felbamate—Leukopenia—Vincristine—lymphatic system cancer	0.000552	0.0011	CcSEcCtD
Felbamate—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00055	0.0011	CcSEcCtD
Felbamate—Chest pain—Carmustine—lymphatic system cancer	0.00055	0.0011	CcSEcCtD
Felbamate—Myalgia—Carmustine—lymphatic system cancer	0.00055	0.0011	CcSEcCtD
Felbamate—Anxiety—Carmustine—lymphatic system cancer	0.000548	0.0011	CcSEcCtD
Felbamate—Paraesthesia—Bleomycin—lymphatic system cancer	0.000542	0.00108	CcSEcCtD
Felbamate—Malaise—Mitoxantrone—lymphatic system cancer	0.000542	0.00108	CcSEcCtD
Felbamate—Dyspnoea—Bleomycin—lymphatic system cancer	0.000538	0.00108	CcSEcCtD
Felbamate—Renal failure acute—Methotrexate—lymphatic system cancer	0.000538	0.00108	CcSEcCtD
Felbamate—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000538	0.00108	CcSEcCtD
Felbamate—Hypertension—Vincristine—lymphatic system cancer	0.000532	0.00107	CcSEcCtD
Felbamate—Confusional state—Carmustine—lymphatic system cancer	0.000532	0.00106	CcSEcCtD
Felbamate—Oedema—Carmustine—lymphatic system cancer	0.000527	0.00105	CcSEcCtD
Felbamate—Decreased appetite—Bleomycin—lymphatic system cancer	0.000525	0.00105	CcSEcCtD
Felbamate—Myalgia—Vincristine—lymphatic system cancer	0.000525	0.00105	CcSEcCtD
Felbamate—Cough—Mitoxantrone—lymphatic system cancer	0.000524	0.00105	CcSEcCtD
Felbamate—Infection—Carmustine—lymphatic system cancer	0.000524	0.00105	CcSEcCtD
Felbamate—Vomiting—Fludarabine—lymphatic system cancer	0.000524	0.00105	CcSEcCtD
Felbamate—Rash—Fludarabine—lymphatic system cancer	0.000519	0.00104	CcSEcCtD
Felbamate—Dermatitis—Fludarabine—lymphatic system cancer	0.000519	0.00104	CcSEcCtD
Felbamate—Hypertension—Mitoxantrone—lymphatic system cancer	0.000518	0.00104	CcSEcCtD
Felbamate—Pain—Bleomycin—lymphatic system cancer	0.000516	0.00103	CcSEcCtD
Felbamate—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000516	0.00103	CcSEcCtD
Felbamate—Headache—Fludarabine—lymphatic system cancer	0.000516	0.00103	CcSEcCtD
Felbamate—Tachycardia—Carmustine—lymphatic system cancer	0.000515	0.00103	CcSEcCtD
Felbamate—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000513	0.00103	CcSEcCtD
Felbamate—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000511	0.00102	CcSEcCtD
Felbamate—Chest pain—Mitoxantrone—lymphatic system cancer	0.000511	0.00102	CcSEcCtD
Felbamate—Myalgia—Mitoxantrone—lymphatic system cancer	0.000511	0.00102	CcSEcCtD
Felbamate—Anxiety—Mitoxantrone—lymphatic system cancer	0.00051	0.00102	CcSEcCtD
Felbamate—Discomfort—Mitoxantrone—lymphatic system cancer	0.000505	0.00101	CcSEcCtD
Felbamate—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000503	0.00101	CcSEcCtD
Felbamate—Oedema—Vincristine—lymphatic system cancer	0.000503	0.00101	CcSEcCtD
Felbamate—Anorexia—Carmustine—lymphatic system cancer	0.000503	0.00101	CcSEcCtD
Felbamate—Infection—Vincristine—lymphatic system cancer	0.0005	0.001	CcSEcCtD
Felbamate—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000498	0.000996	CcSEcCtD
Felbamate—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000497	0.000994	CcSEcCtD
Felbamate—Confusional state—Mitoxantrone—lymphatic system cancer	0.000494	0.000989	CcSEcCtD
Felbamate—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000493	0.000986	CcSEcCtD
Felbamate—Hypotension—Carmustine—lymphatic system cancer	0.000493	0.000985	CcSEcCtD
Felbamate—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00049	0.00098	CcSEcCtD
Felbamate—Oedema—Mitoxantrone—lymphatic system cancer	0.00049	0.00098	CcSEcCtD
Felbamate—Nausea—Fludarabine—lymphatic system cancer	0.000489	0.000979	CcSEcCtD
Felbamate—Infection—Mitoxantrone—lymphatic system cancer	0.000487	0.000974	CcSEcCtD
Felbamate—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000487	0.000973	CcSEcCtD
Felbamate—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00048	0.000961	CcSEcCtD
Felbamate—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00048	0.00096	CcSEcCtD
Felbamate—Urticaria—Bleomycin—lymphatic system cancer	0.00048	0.00096	CcSEcCtD
Felbamate—Anorexia—Vincristine—lymphatic system cancer	0.00048	0.00096	CcSEcCtD
Felbamate—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000478	0.000957	CcSEcCtD
Felbamate—Body temperature increased—Bleomycin—lymphatic system cancer	0.000477	0.000955	CcSEcCtD
Felbamate—Insomnia—Carmustine—lymphatic system cancer	0.000477	0.000954	CcSEcCtD
Felbamate—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000474	0.000948	CcSEcCtD
Felbamate—Paraesthesia—Carmustine—lymphatic system cancer	0.000473	0.000947	CcSEcCtD
Felbamate—Mood swings—Methotrexate—lymphatic system cancer	0.000471	0.000942	CcSEcCtD
Felbamate—Hypotension—Vincristine—lymphatic system cancer	0.00047	0.000941	CcSEcCtD
Felbamate—Dyspnoea—Carmustine—lymphatic system cancer	0.00047	0.00094	CcSEcCtD
Felbamate—Somnolence—Carmustine—lymphatic system cancer	0.000469	0.000938	CcSEcCtD
Felbamate—Anorexia—Mitoxantrone—lymphatic system cancer	0.000467	0.000935	CcSEcCtD
Felbamate—Ataxia—Methotrexate—lymphatic system cancer	0.000467	0.000935	CcSEcCtD
Felbamate—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000459	0.000917	CcSEcCtD
Felbamate—Decreased appetite—Carmustine—lymphatic system cancer	0.000458	0.000917	CcSEcCtD
Felbamate—Hypotension—Mitoxantrone—lymphatic system cancer	0.000458	0.000916	CcSEcCtD
Felbamate—Insomnia—Vincristine—lymphatic system cancer	0.000455	0.000911	CcSEcCtD
Felbamate—Paraesthesia—Vincristine—lymphatic system cancer	0.000452	0.000904	CcSEcCtD
Felbamate—Pain—Carmustine—lymphatic system cancer	0.000451	0.000902	CcSEcCtD
Felbamate—Constipation—Carmustine—lymphatic system cancer	0.000451	0.000902	CcSEcCtD
Felbamate—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000447	0.000895	CcSEcCtD
Felbamate—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000447	0.000893	CcSEcCtD
Felbamate—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00044	0.00088	CcSEcCtD
Felbamate—Decreased appetite—Vincristine—lymphatic system cancer	0.000437	0.000875	CcSEcCtD
Felbamate—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000437	0.000874	CcSEcCtD
Felbamate—Somnolence—Mitoxantrone—lymphatic system cancer	0.000436	0.000872	CcSEcCtD
Felbamate—Feeling abnormal—Carmustine—lymphatic system cancer	0.000434	0.000869	CcSEcCtD
Felbamate—Fatigue—Vincristine—lymphatic system cancer	0.000434	0.000868	CcSEcCtD
Felbamate—Asthenia—Bleomycin—lymphatic system cancer	0.000433	0.000867	CcSEcCtD
Felbamate—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000431	0.000863	CcSEcCtD
Felbamate—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000431	0.000862	CcSEcCtD
Felbamate—Pain—Vincristine—lymphatic system cancer	0.00043	0.000861	CcSEcCtD
Felbamate—Constipation—Vincristine—lymphatic system cancer	0.00043	0.000861	CcSEcCtD
Felbamate—Asthma—Methotrexate—lymphatic system cancer	0.000429	0.000859	CcSEcCtD
Felbamate—Pruritus—Bleomycin—lymphatic system cancer	0.000427	0.000855	CcSEcCtD
Felbamate—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000426	0.000852	CcSEcCtD
Felbamate—Eosinophilia—Methotrexate—lymphatic system cancer	0.000425	0.000851	CcSEcCtD
Felbamate—Fatigue—Mitoxantrone—lymphatic system cancer	0.000423	0.000845	CcSEcCtD
Felbamate—Pancreatitis—Methotrexate—lymphatic system cancer	0.000421	0.000842	CcSEcCtD
Felbamate—Constipation—Mitoxantrone—lymphatic system cancer	0.000419	0.000838	CcSEcCtD
Felbamate—Pain—Mitoxantrone—lymphatic system cancer	0.000419	0.000838	CcSEcCtD
Felbamate—Body temperature increased—Carmustine—lymphatic system cancer	0.000417	0.000834	CcSEcCtD
Felbamate—Abdominal pain—Carmustine—lymphatic system cancer	0.000417	0.000834	CcSEcCtD
Felbamate—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000412	0.000823	CcSEcCtD
Felbamate—Pancytopenia—Methotrexate—lymphatic system cancer	0.000408	0.000816	CcSEcCtD
Felbamate—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000404	0.000808	CcSEcCtD
Felbamate—Dysuria—Methotrexate—lymphatic system cancer	0.000402	0.000803	CcSEcCtD
Felbamate—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000401	0.000802	CcSEcCtD
Felbamate—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000399	0.000798	CcSEcCtD
Felbamate—Abdominal pain—Vincristine—lymphatic system cancer	0.000398	0.000796	CcSEcCtD
Felbamate—Body temperature increased—Vincristine—lymphatic system cancer	0.000398	0.000796	CcSEcCtD
Felbamate—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000392	0.000784	CcSEcCtD
Felbamate—Urticaria—Mitoxantrone—lymphatic system cancer	0.000389	0.000779	CcSEcCtD
Felbamate—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000387	0.000775	CcSEcCtD
Felbamate—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000387	0.000775	CcSEcCtD
Felbamate—Pneumonia—Methotrexate—lymphatic system cancer	0.000385	0.00077	CcSEcCtD
Felbamate—Vomiting—Bleomycin—lymphatic system cancer	0.000384	0.000768	CcSEcCtD
Felbamate—Depression—Methotrexate—lymphatic system cancer	0.000382	0.000764	CcSEcCtD
Felbamate—Rash—Bleomycin—lymphatic system cancer	0.000381	0.000762	CcSEcCtD
Felbamate—Dermatitis—Bleomycin—lymphatic system cancer	0.00038	0.000761	CcSEcCtD
Felbamate—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00038	0.000759	CcSEcCtD
Felbamate—Asthenia—Carmustine—lymphatic system cancer	0.000378	0.000757	CcSEcCtD
Felbamate—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000372	0.000745	CcSEcCtD
Felbamate—Sweating—Methotrexate—lymphatic system cancer	0.000367	0.000734	CcSEcCtD
Felbamate—Haematuria—Methotrexate—lymphatic system cancer	0.000365	0.00073	CcSEcCtD
Felbamate—Epistaxis—Methotrexate—lymphatic system cancer	0.000361	0.000722	CcSEcCtD
Felbamate—Asthenia—Vincristine—lymphatic system cancer	0.000361	0.000722	CcSEcCtD
Felbamate—Diarrhoea—Carmustine—lymphatic system cancer	0.000361	0.000722	CcSEcCtD
Felbamate—Nausea—Bleomycin—lymphatic system cancer	0.000359	0.000718	CcSEcCtD
Felbamate—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000357	0.000715	CcSEcCtD
Felbamate—Asthenia—Mitoxantrone—lymphatic system cancer	0.000352	0.000703	CcSEcCtD
Felbamate—Dizziness—Carmustine—lymphatic system cancer	0.000349	0.000697	CcSEcCtD
Felbamate—Haemoglobin—Methotrexate—lymphatic system cancer	0.000345	0.000691	CcSEcCtD
Felbamate—Diarrhoea—Vincristine—lymphatic system cancer	0.000344	0.000689	CcSEcCtD
Felbamate—Haemorrhage—Methotrexate—lymphatic system cancer	0.000344	0.000688	CcSEcCtD
Felbamate—Hepatitis—Methotrexate—lymphatic system cancer	0.000344	0.000688	CcSEcCtD
Felbamate—Pharyngitis—Methotrexate—lymphatic system cancer	0.000341	0.000682	CcSEcCtD
Felbamate—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000335	0.000671	CcSEcCtD
Felbamate—Vomiting—Carmustine—lymphatic system cancer	0.000335	0.000671	CcSEcCtD
Felbamate—Dizziness—Vincristine—lymphatic system cancer	0.000333	0.000666	CcSEcCtD
Felbamate—Rash—Carmustine—lymphatic system cancer	0.000332	0.000665	CcSEcCtD
Felbamate—Dermatitis—Carmustine—lymphatic system cancer	0.000332	0.000664	CcSEcCtD
Felbamate—Visual impairment—Methotrexate—lymphatic system cancer	0.000331	0.000663	CcSEcCtD
Felbamate—Headache—Carmustine—lymphatic system cancer	0.00033	0.000661	CcSEcCtD
Felbamate—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000325	0.00065	CcSEcCtD
Felbamate—Vomiting—Vincristine—lymphatic system cancer	0.00032	0.00064	CcSEcCtD
Felbamate—Rash—Vincristine—lymphatic system cancer	0.000317	0.000635	CcSEcCtD
Felbamate—Dermatitis—Vincristine—lymphatic system cancer	0.000317	0.000634	CcSEcCtD
Felbamate—Headache—Vincristine—lymphatic system cancer	0.000315	0.000631	CcSEcCtD
Felbamate—Nausea—Carmustine—lymphatic system cancer	0.000313	0.000626	CcSEcCtD
Felbamate—Vomiting—Mitoxantrone—lymphatic system cancer	0.000312	0.000623	CcSEcCtD
Felbamate—Rash—Mitoxantrone—lymphatic system cancer	0.000309	0.000618	CcSEcCtD
Felbamate—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000309	0.000618	CcSEcCtD
Felbamate—Chills—Methotrexate—lymphatic system cancer	0.000308	0.000617	CcSEcCtD
Felbamate—Headache—Mitoxantrone—lymphatic system cancer	0.000307	0.000614	CcSEcCtD
Felbamate—Alopecia—Methotrexate—lymphatic system cancer	0.000304	0.000608	CcSEcCtD
Felbamate—Nausea—Vincristine—lymphatic system cancer	0.000299	0.000598	CcSEcCtD
Felbamate—Dysgeusia—Methotrexate—lymphatic system cancer	0.000293	0.000586	CcSEcCtD
Felbamate—Nausea—Mitoxantrone—lymphatic system cancer	0.000291	0.000582	CcSEcCtD
Felbamate—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000278	0.000555	CcSEcCtD
Felbamate—Anaemia—Methotrexate—lymphatic system cancer	0.000277	0.000553	CcSEcCtD
Felbamate—Malaise—Methotrexate—lymphatic system cancer	0.00027	0.00054	CcSEcCtD
Felbamate—Leukopenia—Methotrexate—lymphatic system cancer	0.000268	0.000536	CcSEcCtD
Felbamate—Cough—Methotrexate—lymphatic system cancer	0.000261	0.000522	CcSEcCtD
Felbamate—Chest pain—Methotrexate—lymphatic system cancer	0.000255	0.00051	CcSEcCtD
Felbamate—Myalgia—Methotrexate—lymphatic system cancer	0.000255	0.00051	CcSEcCtD
Felbamate—Arthralgia—Methotrexate—lymphatic system cancer	0.000255	0.00051	CcSEcCtD
Felbamate—Discomfort—Methotrexate—lymphatic system cancer	0.000252	0.000503	CcSEcCtD
Felbamate—Confusional state—Methotrexate—lymphatic system cancer	0.000246	0.000493	CcSEcCtD
Felbamate—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000244	0.000489	CcSEcCtD
Felbamate—Infection—Methotrexate—lymphatic system cancer	0.000243	0.000485	CcSEcCtD
Felbamate—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000239	0.000478	CcSEcCtD
Felbamate—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000236	0.000472	CcSEcCtD
Felbamate—Anorexia—Methotrexate—lymphatic system cancer	0.000233	0.000466	CcSEcCtD
Felbamate—Hypotension—Methotrexate—lymphatic system cancer	0.000228	0.000456	CcSEcCtD
Felbamate—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000222	0.000445	CcSEcCtD
Felbamate—Insomnia—Methotrexate—lymphatic system cancer	0.000221	0.000442	CcSEcCtD
Felbamate—Paraesthesia—Methotrexate—lymphatic system cancer	0.000219	0.000439	CcSEcCtD
Felbamate—Dyspnoea—Methotrexate—lymphatic system cancer	0.000218	0.000436	CcSEcCtD
Felbamate—Somnolence—Methotrexate—lymphatic system cancer	0.000217	0.000434	CcSEcCtD
Felbamate—Dyspepsia—Methotrexate—lymphatic system cancer	0.000215	0.00043	CcSEcCtD
Felbamate—Decreased appetite—Methotrexate—lymphatic system cancer	0.000212	0.000425	CcSEcCtD
Felbamate—Fatigue—Methotrexate—lymphatic system cancer	0.000211	0.000421	CcSEcCtD
Felbamate—Pain—Methotrexate—lymphatic system cancer	0.000209	0.000418	CcSEcCtD
Felbamate—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000201	0.000403	CcSEcCtD
Felbamate—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.0002	0.000399	CcSEcCtD
Felbamate—Urticaria—Methotrexate—lymphatic system cancer	0.000194	0.000388	CcSEcCtD
Felbamate—Abdominal pain—Methotrexate—lymphatic system cancer	0.000193	0.000386	CcSEcCtD
Felbamate—Body temperature increased—Methotrexate—lymphatic system cancer	0.000193	0.000386	CcSEcCtD
Felbamate—Asthenia—Methotrexate—lymphatic system cancer	0.000175	0.00035	CcSEcCtD
Felbamate—Pruritus—Methotrexate—lymphatic system cancer	0.000173	0.000346	CcSEcCtD
Felbamate—Diarrhoea—Methotrexate—lymphatic system cancer	0.000167	0.000334	CcSEcCtD
Felbamate—Dizziness—Methotrexate—lymphatic system cancer	0.000161	0.000323	CcSEcCtD
Felbamate—Vomiting—Methotrexate—lymphatic system cancer	0.000155	0.000311	CcSEcCtD
Felbamate—Rash—Methotrexate—lymphatic system cancer	0.000154	0.000308	CcSEcCtD
Felbamate—Dermatitis—Methotrexate—lymphatic system cancer	0.000154	0.000308	CcSEcCtD
Felbamate—Headache—Methotrexate—lymphatic system cancer	0.000153	0.000306	CcSEcCtD
Felbamate—Nausea—Methotrexate—lymphatic system cancer	0.000145	0.00029	CcSEcCtD
